Abstract:Background Peritoneal dissemination (PD) is the most common mode of metastasis for advanced gastric cancer (GC) with poor prognosis. It is of great significance to accurately predict preoperative PD and develop optimal treatment strategies for GC patients. Our study assessed the diagnostic potential of serum tumor markers and clinicopathologic features, to improve the accuracy of predicting the presence of PD in GC patients. Methods In our study, 1264 patients with GC at Fudan University Shanghai Cancer Center and Wenzhou people’s hospital from 2018 to 2020 were retrospectively analyzed, including 316 cases of PD and 948 cases without PD. All patients underwent enhanced CT scan or magnetic resonance imaging (MRI) before surgery and treatment. Clinicopathological features, including tumor diameter and tumor stage (depth of tumor invasion, nearby lymph node metastasis and distant metastasis), were obtained by imaging examination. The independent risk factors for PD were screened through univariate and multivariate logistic regression analyses, and the results were expressed with 95% confidence intervals (CIs). A model of PD diagnosis and prediction was established by using Cox proportional hazards regression model of training set. Furthermore, the accuracy of the prediction model was verified by ROC curve and calibration plots. Results Univariate analysis showed that PD in GC was significantly related to tumor diameter (odds ratio (OR)=12.06, p<0.0006), depth of invasion (OR=14.55, p<0.0001), lymph node metastases (OR=5.89, p<0.0001), carcinoembryonic antigen (CEA) (OR=2.50, p<0.0001), CA125 (OR=11.46, p<0.0001), CA72-4 (OR=4.09, p<0.0001), CA19-9 (OR=2.74, p<0.0001), CA50 (OR=5.20, p<0.0001) and CA242 (OR=3.83, p<0.0001). Multivariate analysis revealed that clinical invasion depth and serum marker of CA125 and CA72-4 were independent risk factors for PD. The prediction model was established based on the risk factors using the R program. The area under the curve (AUC) of the receiver operating characteristics (ROC) was 0.931 (95% CI: 0.900–0.960), with the accuracy, sensitivity and specificity values of 90.5%, 86.2% and 82.2%, respectively. Conclusion The nomogram model constructed using CA125, CA72-4 and depth of invasion increases the accuracy and sensitivity in predicting the incidence of PD in GC patients and can be used as an important tool for preoperative diagnosis.

Predicting Peritoneal Dissemination Of Gastric Cancer In The Era Of Precision Medicine: Molecular Characterization And Biomarkers

PD-L1 and Gastric Cancer Prognosis: A Systematic Review and Meta-Analysis

Emerging Molecular Basis of Hematogenous Metastasis in Gastric Cancer

Approaches and Genetic Determinants in Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer

Comprehensive Roles and Future Perspectives of Exosomes in Peritoneal Metastasis of Gastric Cancer

Construction of a Nomogram Model for Predicting Peritoneal Dissemination in Gastric Cancer Based on Clinicopathologic Features and Preoperative Serum Tumor Markers

Integrated Assessment of PD-L1 Expression and Molecular Classification Facilitates Therapy Selection and Prognosis Prediction in Gastric Cancer

Biomarkers for Precision Treatment in Gastric Cancer

Cmar_a_206189 6397..6410

Analysis and External Validation of a Nomogram to Predict Peritoneal Dissemination in Gastric Cancer.

Current and future molecular diagnostics of gastric cancer

Recent Progress in Genetic and Epigenetic Profile of Diffuse Gastric Cancer

Molecular determinants of peritoneal dissemination in gastric adenocarcinoma

[Diagnostic methods for peritoneal molecular residual disease in gastric cancer]

Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer

Molecular Pathogenesis of Gastric Adenocarcinoma

Gastric cancer treatment: recent progress and future perspectives

Emerging Molecular Classifications and Therapeutic Implications for Gastric Cancer

Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.